The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat

about

Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat

P2860

Q34795714-17F21A3F-91EF-4A87-A892-2BB5A9698445 Q35815701-1AD9DEA3-ADC9-4FD8-BF0C-A8D07DB43EC4

P2860

The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat

Item

http://www.wikidata.org/entity/Q36852272

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

The effects of BMY-14802 again ...... ia in the hemiparkinsonian rat

@en

type

Item

label

The effects of BMY-14802 again ...... ia in the hemiparkinsonian rat

@en

prefLabel

The effects of BMY-14802 again ...... ia in the hemiparkinsonian rat

@en

P1476

The effects of BMY-14802 again ...... ia in the hemiparkinsonian rat

@en

P2093

Adam A Goldenberg

http://www.w3.org/2001/XMLSchema#string

Christopher Bishop

http://www.w3.org/2001/XMLSchema#string

Margaret A Surrena

http://www.w3.org/2001/XMLSchema#string

Melanie A Paquette

http://www.w3.org/2001/XMLSchema#string

Nirmal Bhide

http://www.w3.org/2001/XMLSchema#string

S Paul Berger

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinson's disease: clinical features and diagnosis

The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism

Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease

D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys

Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.

L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.

Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

P2888

s00213-013-3001-4

P304

533-544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00213-013-3001-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

227

http://www.w3.org/2001/XMLSchema#string

P50

David Lindenbach

P577

2013-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235416177

http://www.w3.org/2001/XMLSchema#string

P698

23389756

http://www.w3.org/2001/XMLSchema#string

P921

dyskinesia

P932

3657017

http://www.w3.org/2001/XMLSchema#string

The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat

about

P2860

P2860

The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932